DeuterOncology is a preclinical-stage biotech company.
DeuterOncology has raised $6.1M in total funding. The most recent round was Series A. The last funding was announced in January 2023.
DeuterOncology's investors include Newton Biocapital, Investsud, Meusinvest (Noshaq).
DeuterOncology is headquartered in Geel, Belgium.
DeuterOncology is a preclinical-stage biotech company.
DeuterOncology is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"DeuterOncology — Funding & Investors." VCBacked, January 19, 2023, https://www.vcbacked.co/company/deuteroncology. Accessed September 30, 2026.
VCBacked. (2023). DeuterOncology — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/deuteroncology
{{cite web |title=DeuterOncology — Funding & Investors |url=https://www.vcbacked.co/company/deuteroncology |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated